-

Shareholder Alert: Robbins LLP Announces Eastman Kodak Co. (KODK) Accused of Misleading Shareholders

SAN DIEGO & ROCHESTER, N.Y.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Eastman Kodak Co. (NYSE:KODK) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between July 27, 2020 and August 7, 2020. Eastman Kodak is a technology company that provides hardware, software, and services to customers in commercial print, packaging, publishing, manufacturing, and entertainment.

If you suffered a loss due to Kodak's misconduct, click here.

Kodak (KODK) Executives Receive Stock Option Grants Prior to Explosion in Stock Price

On July 27, 2020, Kodak granted its CEO and Executive Chairman 1.75 million stock options, and 45,000 options each to its CFO, VP, and General Counsel. That same day, Kodak issued a statement to media outlets based in Rochester, NY, regarding "a new manufacturing initiative that could change the course of history for Rochester and the American People." Media reports noted there would be a press conference the next day with Pentagon officials and that the initiative involved the U.S. International Development Finance Corporation ("DFC") and the response to COVID-19. On this news, Kodak's trading volume surged and the stock price increased. On July 28, before the stock market opened, RochesterFirst.com published an article revealing that Kodak and Washington D.C. leaders announced an agreement for a $765 million federal loan to support the launch of Kodak Pharmaceuticals. Kodak executives spent the next several days touting this agreement and watching Kodak's stock price increase over 1,000%, from $2.65 on July 27, to $33.20 on July 29. Simultaneously, the insiders who received options saw their personal worth skyrocket. On August 1, 2020, questions started to arise regarding Kodak's selection for the federal loan, the way Kodak handled the "inadvertent" disclosure on July 27, and Kodak's failure to disclose the deal to investors. Revelations surrounding these questions caused Kodak's stock to plummet over $29 per share over four trading days. Finally, on August 7, the DFC announced it will not proceed with the loan process until allegations against Kodak are cleared up, causing the stock to drop another 28% to close at $10.73 on August 10, 2020. Kodak is currently under investigation by several House Congressional committees and the SEC.

Kodak (KODK) Shareholders Have Legal Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Kodak settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Masonite International Corporation (k/n/a Owens Corning's Doors) Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all sellers of Masonite International Corporation (NYSE: DOOR) (k/n/a Owens Corning's Doors) common stock between June 5, 2023 and February 8, 2024. Masonite is a leading global designer, manufacturer, marketer, and distributor of interior and exterior doors and door solutions for the residential and non-residential building construction markets’ new construction and repair, renovation and re...
Back to Newsroom